Skip to content

Study · In vitro (cells) · 2025

3 results

The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy.

Gatta M, Dovizio M, Milillo C, Ruggieri AG, Sallese M, Antonucci I, Trofimov A, Khavinson V, Trofimova S, Bruno A, Ballerini P

Stem cell reviews and reports10 Jun 2025Cited by 1 (Europe PMC)

PMID40493162 (opens in a new tab)PMCIDPMC12356729 (opens in a new tab)DOI10.1007/s12015-025-10911-x (opens in a new tab)PepBankPUB-40493162
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In high-glucose-injured ARPE-19 cells, Epitalon restored impaired wound healing.

    In plain wordsIn lab-grown eye cells damaged by high glucose, Epitalon restored slowed wound healing.

    Peptide
    Epitalon
    Outcome
    IncreaseWound healing in high-glucose-injured cells
    Study

    humann: not reported in source

    High glucose-injured ARPE-19 retinal pigment epithelial cells
    Outcome group
    Wound healing · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The antioxidant Epitalon restored impaired wound healing in HG-injured ARPE-19 cells
    1 context sentence
    Summary · context
    This study aims to test the hypothesis that the antioxidant effect of the synthetic tetrapeptide AEDG (Ala-Glu-Asp-Gly, Epitalon) improves the delayed healing process associated with hyperglycemia in DR, using a high glucose (HG)-injured human retinal pigment epithelial cell line (ARPE-19).
  2. 02LabIn vitro (cells)Activity measurement

    In high-glucose-injured ARPE-19 cells, Epitalon inhibited hyperglycemia-induced epithelial-mesenchymal transition.

    In plain wordsIn lab-grown eye cells damaged by high glucose, Epitalon reduced a cell change linked to scarring.

    Peptide
    Epitalon
    Outcome
    DecreaseHyperglycemia-induced epithelial-mesenchymal transition
    Study

    humann: not reported in source

    High glucose-injured ARPE-19 retinal pigment epithelial cells
    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The antioxidant Epitalon restored impaired wound healing in HG-injured ARPE-19 cells by inhibiting hyperglycemia-induced EMT and fibrosis.
    1 context sentence
    Summary · context
    This study aims to test the hypothesis that the antioxidant effect of the synthetic tetrapeptide AEDG (Ala-Glu-Asp-Gly, Epitalon) improves the delayed healing process associated with hyperglycemia in DR, using a high glucose (HG)-injured human retinal pigment epithelial cell line (ARPE-19).
  3. 03LabIn vitro (cells)Activity measurement

    In high-glucose-injured ARPE-19 cells, Epitalon inhibited hyperglycemia-induced fibrosis.

    In plain wordsIn lab-grown eye cells damaged by high glucose, Epitalon reduced scarring-related changes.

    Peptide
    Epitalon
    Outcome
    DecreaseHyperglycemia-induced fibrosis
    Study

    humann: not reported in source

    High glucose-injured ARPE-19 retinal pigment epithelial cells
    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The antioxidant Epitalon restored impaired wound healing in HG-injured ARPE-19 cells by inhibiting hyperglycemia-induced EMT and fibrosis.
    1 context sentence
    Summary · context
    This study aims to test the hypothesis that the antioxidant effect of the synthetic tetrapeptide AEDG (Ala-Glu-Asp-Gly, Epitalon) improves the delayed healing process associated with hyperglycemia in DR, using a high glucose (HG)-injured human retinal pigment epithelial cell line (ARPE-19).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.